{"id":63916,"date":"2026-04-24T21:03:52","date_gmt":"2026-04-24T13:03:52","guid":{"rendered":"https:\/\/flcube.com\/?p=63916"},"modified":"2026-04-24T21:03:55","modified_gmt":"2026-04-24T13:03:55","slug":"china-medical-systems-comekibart-anti-il-4r%ce%b1-antibody-enters-nmpa-review-for-seasonal-allergic-rhinitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63916","title":{"rendered":"China Medical System&#8217;s Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis"},"content":{"rendered":"\n<p><strong>China Medical System Holdings Limited<\/strong> (CMS; <a href=\"https:\/\/www.google.com\/finance\/quote\/0867:HKG\">HKG: 0867<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted for review its marketing approval filing for <strong>comekibart (MG-K10)<\/strong>, an anti-IL-4R\u03b1 antibody licensed from domestic biotech firm <strong>Hunan MabGeek Biotech Co., Ltd.<\/strong> in January 2025. The application targets treatment of moderate-to-severe seasonal allergic rhinitis with inadequate symptom control following intranasal glucocorticoid therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>China Medical System Holdings (HKG: 0867)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Comekibart (MG-K10)<\/td><\/tr><tr><td><strong>Molecule Type<\/strong><\/td><td>Anti-IL-4R\u03b1 monoclonal antibody<\/td><\/tr><tr><td><strong>Licensing Partner<\/strong><\/td><td>Hunan MabGeek Biotech Co., Ltd.<\/td><\/tr><tr><td><strong>License Date<\/strong><\/td><td>January 2025<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Review Status<\/strong><\/td><td>Marketing application accepted for review<\/td><\/tr><tr><td><strong>Primary Indication<\/strong><\/td><td>Moderate-to-severe seasonal allergic rhinitis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-mechanism-amp-development-pipeline\">Therapeutic Mechanism &amp; Development Pipeline<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dual-cytokine-inhibition\">Dual Cytokine Inhibition<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: IL-4R\u03b1 receptor<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Simultaneous blockade of <strong>IL-4 and IL-13<\/strong> signaling pathways<\/li>\n\n\n\n<li><strong>Effect<\/strong>: Immunomodulatory action targeting type 2 inflammatory responses<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Addresses root cause of inflammation rather than symptomatic relief<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-broad-type-2-inflammatory-disease-portfolio\">Broad Type 2 Inflammatory Disease Portfolio<\/h3>\n\n\n\n<p>Comekibart is being developed for multiple indications including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Seasonal allergic rhinitis (primary NMPA filing)<\/li>\n\n\n\n<li>Asthma<\/li>\n\n\n\n<li>Atopic dermatitis (AD)<\/li>\n\n\n\n<li>Prurigo nodularis<\/li>\n\n\n\n<li>Chronic obstructive pulmonary disease (COPD)<\/li>\n\n\n\n<li>Chronic spontaneous urticaria (CSU)<\/li>\n\n\n\n<li>Chronic rhinosinusitis with nasal polyps<\/li>\n\n\n\n<li>Eosinophilic esophagitis<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Seasonal Allergic Rhinitis<\/strong>: Affects an estimated 150-200 million people in China<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Significant unmet need for patients with inadequate response to intranasal glucocorticoids<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Potential to compete with established IL-4R\u03b1 inhibitors like dupilumab<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-domestic-innovation-focus\">Domestic Innovation Focus<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Local Licensing<\/strong>: Represents strategic partnership between established pharmaceutical company and emerging Chinese biotech<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Leverages NMPA&#8217;s expedited review programs for innovative domestic therapies<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: CMS&#8217;s established distribution network provides rapid market access upon approval<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-next-steps\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<p>The NMPA review process typically takes 12-18 months for standard applications, though priority review may accelerate approval. CMS&#8217;s successful navigation of this regulatory milestone positions comekibart as a potential first-in-class Chinese-developed IL-4R\u03b1 inhibitor for allergic conditions.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory timelines, clinical development, and commercial expectations for comekibart. Actual approval dates, market access, and competitive positioning may differ based on regulatory decisions, clinical outcomes, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042302207_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026042302207_c.\"><\/object><a id=\"wp-block-file--media-57479629-b402-4bcd-801c-6b933cc848c0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042302207_c.pdf\">2026042302207_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042302207_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-57479629-b402-4bcd-801c-6b933cc848c0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[325,844,38],"class_list":["post-63916","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-china-medical-system","tag-hkg-0867","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Medical System&#039;s Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing approval filing for comekibart (MG-K10), an anti-IL-4R\u03b1 antibody licensed from domestic biotech firm Hunan MabGeek Biotech Co., Ltd. in January 2025. The application targets treatment of moderate-to-severe seasonal allergic rhinitis with inadequate symptom control following intranasal glucocorticoid therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63916\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Medical System&#039;s Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis\" \/>\n<meta property=\"og:description\" content=\"China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing approval filing for comekibart (MG-K10), an anti-IL-4R\u03b1 antibody licensed from domestic biotech firm Hunan MabGeek Biotech Co., Ltd. in January 2025. The application targets treatment of moderate-to-severe seasonal allergic rhinitis with inadequate symptom control following intranasal glucocorticoid therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63916\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-24T13:03:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-24T13:03:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63916#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63916\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Medical System&#8217;s Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis\",\"datePublished\":\"2026-04-24T13:03:52+00:00\",\"dateModified\":\"2026-04-24T13:03:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63916\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"China Medical System\",\"HKG: 0867\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63916#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63916\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63916\",\"name\":\"China Medical System's Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-24T13:03:52+00:00\",\"dateModified\":\"2026-04-24T13:03:55+00:00\",\"description\":\"China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing approval filing for comekibart (MG-K10), an anti-IL-4R\u03b1 antibody licensed from domestic biotech firm Hunan MabGeek Biotech Co., Ltd. in January 2025. The application targets treatment of moderate-to-severe seasonal allergic rhinitis with inadequate symptom control following intranasal glucocorticoid therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63916#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63916\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63916#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Medical System&#8217;s Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Medical System's Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry","description":"China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing approval filing for comekibart (MG-K10), an anti-IL-4R\u03b1 antibody licensed from domestic biotech firm Hunan MabGeek Biotech Co., Ltd. in January 2025. The application targets treatment of moderate-to-severe seasonal allergic rhinitis with inadequate symptom control following intranasal glucocorticoid therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63916","og_locale":"en_US","og_type":"article","og_title":"China Medical System's Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis","og_description":"China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing approval filing for comekibart (MG-K10), an anti-IL-4R\u03b1 antibody licensed from domestic biotech firm Hunan MabGeek Biotech Co., Ltd. in January 2025. The application targets treatment of moderate-to-severe seasonal allergic rhinitis with inadequate symptom control following intranasal glucocorticoid therapy.","og_url":"https:\/\/flcube.com\/?p=63916","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-24T13:03:52+00:00","article_modified_time":"2026-04-24T13:03:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63916#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63916"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Medical System&#8217;s Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis","datePublished":"2026-04-24T13:03:52+00:00","dateModified":"2026-04-24T13:03:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63916"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["China Medical System","HKG: 0867","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63916#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63916","url":"https:\/\/flcube.com\/?p=63916","name":"China Medical System's Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-24T13:03:52+00:00","dateModified":"2026-04-24T13:03:55+00:00","description":"China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration (NMPA) has accepted for review its marketing approval filing for comekibart (MG-K10), an anti-IL-4R\u03b1 antibody licensed from domestic biotech firm Hunan MabGeek Biotech Co., Ltd. in January 2025. The application targets treatment of moderate-to-severe seasonal allergic rhinitis with inadequate symptom control following intranasal glucocorticoid therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63916#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63916"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63916#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Medical System&#8217;s Comekibart Anti-IL-4R\u03b1 Antibody Enters NMPA Review for Seasonal Allergic Rhinitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63916"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63916\/revisions"}],"predecessor-version":[{"id":63918,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63916\/revisions\/63918"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}